Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Earnings Miss Sets Up a More Complex Picture for Zymeworks
Zymeworks (ZYME) just posted a wider quarterly loss and lower than expected revenue, while also highlighting upcoming FDA and pipeline milestones that could shape how you think about the stock over the next year.
See our latest analysis for Zymeworks.
The earnings miss helped drive a 1 day share price return of 3.66% decline and a 7 day share price return of 3.41% decline, yet the 90 day share price return of 17.08% and 1 year total shareholder return of very large suggest momentum has been building over a longer stretch.
If this kind of earnings driven move has your attention, it could be a good moment to look at other biotech ideas powered by AI through the 35 healthcare AI stocks.
With shares up 17.08% over 90 days and a very large 1 year total return, yet still trading below some estimated value markers, the real question is whether Zymeworks is still mispriced or if the market is already accounting for future growth.
Most Popular Narrative: 33.6% Undervalued
The most followed narrative pegs Zymeworks’ fair value at $40.08 versus a last close of $26.60, framing the stock as materially discounted on that view.
The analysts have a consensus price target of $40.08 for Zymeworks based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $58.0, and the most bearish reporting a price target of just $31.0.
Curious what has to happen for that gap to close? The narrative leans on fast improving earnings, richer margins, and a premium future profit multiple. The exact mix of growth, dilution and discount rate assumptions might surprise you.
Result: Fair Value of $40.08 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, this depends on partners meeting clinical and regulatory milestones on schedule, and on early stage pipeline assets avoiding setbacks that could disrupt expected royalty streams.
Find out about the key risks to this Zymeworks narrative.
Next Steps
With that optimism in mind, do not just rely on headlines or a single narrative; move quickly, review the details, and see what stands out in the 3 key rewards
Ready to hunt for more opportunities?
If Zymeworks is on your radar, do not stop there. Broaden your watchlist with other ideas that match your goals and risk comfort.